Phaseline

Targets › ELN

ELN (Elastin): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Other.

Major structural protein of tissues such as aorta and nuchal ligament, which must expand rapidly and recover completely. Molecular determinant of the late arterial morphogenesis, stabilizing arterial structure by regulating proliferation and organization of vascular smooth muscle (By similarity). (UniProt, P15502)

Open in Phaseline: the race on ELN, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Krystal BiotechKB304
HSV-1 vector delivering human collagen (COL3) and elastin (tropoelastin) genes
COL3, ELNPhase 1Wrinkles in Decolletage–

Conditions

Wrinkles in Decolletage (1)

Modalities

protein or peptide (1)

Companies

Krystal Biotech (1)

Related targets

COL3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.